UNAIDS/WHO 2015 | Reference
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.14
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.12
HIV patient monitoring and case surveillance
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
Policy Brief
HIV testing services
December 2016
WHO/HIV/2016.21
The report showed commitments made three decades ago to protect the rights of children remain unfulfilled for millions. Violence still affects countless children. Discrimination based on age, gender, disability, sexual orientation and religion harms children worldwide.
The UN Convention on the Ri...ghts of the Child is the most widely ratified international human rights treaty in history. It has prompted substantial investment in children’s health, education and safety and the adoption of laws and policies that recognise the rights of children, particularly in areas where they are vulnerable, including labour exploitation, corporal punishment, alternative care and forced and early marriage.
more
Overview
Rev Panam Salud Publica 40(6), 2016
Disease outbreak news, 21 November 2019
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0189770 January 2, 2018
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
National HIV curriculum
You can always find the most up to date version of this document at
https://www.hiv.uw.edu/go/co-occurring-conditions/opportunistic-infections-prevention/coreconcept/all
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more